In brief
In a significant move to lower prescription drug costs, Medicare has added 15 new medications to its drug price negotiation program. These include treatments for Type 2 diabetes, HIV, and arthritis. Negotiations could yield substantial savings for Medicare enrollees when the new prices take effect in 2028. This expansion emphasizes the importance of making healthcare affordable for seniors and taxpayers amidst rising drug costs.
NEW YORK (AP) — Medicare has unveiled plans to negotiate prices for 15 new medications, including key treatments for Type 2 diabetes, HIV, and arthritis, as part of the ongoing effort to control escalating prescription drug costs. The announcement made by the Centers for Medicare and Medicaid Services (CMS) aims to ensure fair pricing and better access for enrollees, emphasizing the government's commitment to address soaring healthcare expenses.
The selected medications are among the highest in spending under Medicare, which means effective negotiations could lead to significant taxpayer savings when the amendments take effect in 2028. This reform is seen as a critical step towards making healthcare more accessible, especially for America's senior citizens.
For too long, seniors and taxpayers have paid the price for skyrocketing prescription drug costs, said CMS Administrator Dr. Mehmet Oz, highlighting the agency's initiative to engage with pharmaceutical companies for fairer prices. This latest move follows previous negotiations that successfully reduced prices for 25 other medications, including popular diabetes drugs.
This year's negotiations mark a major development as it also includes drugs covered under Medicare Part B, which encompasses outpatient medications. The newly negotiated drugs include not only diabetes treatments like Trulicity but also Biktarvy for HIV and Botox for specific medical uses.
Significant engagement from stakeholders has emerged, with AARP expressing their support for these negotiations as vital for older Americans. Meanwhile, pharmaceutical companies have criticized the framework put in place by the Inflation Reduction Act, labeling government price setting as detrimental. The ongoing dialogue about drug pricing reflects the pressing necessity for reform in the American healthcare landscape.
The full list of newly negotiated drugs includes rarely discussed yet valuable treatments such as Lenvima for cancer and Verzenio for different oncological conditions, reinforcing the importance of affordability across diverse health concerns.
